Evidence map›Paper›PMID 42774152›Full record

ArticleFrontiers in immunology2026

Multi-epitope vaccine targeting SARS-CoV-2 omicron S and N proteins promotes enhanced immunity: a computational approach.

Xinyi Xu, Arslan Habib, Naishuo Zhu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinyi XuLaboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
Arslan HabibDepartment of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Naishuo ZhuLaboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the COVID-19 pandemic, which resulted in millions of deaths globally and had profound social, economic, and political consequences. Although effective vaccines and antiviral therapies have substantially reduced the global burden of COVID-19, the continued emergence of viral variants highlights the need for next-generation effective vaccine strategies capable of providing broader and more durable immune response. Methods: In this work, we provide an immunoinformatic approach for multi-epitope vaccine (MEV) design and prediction. Based on the spike (S) and nucleocapsid (N) proteins of SARS-CoV-2, immunoinformatic methods were used to identify the epitopes for B cells, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL). The B cell, CTL, and HTL epitopes were conjugated with flexible linkers GSG, GSGG, and a Gb-1 peptide conjugated to the C-terminal of the MEV ccandidate. Results: The final MEV candidate exhibited favorable predicted characteristics, with a molecular weight of approximately 55.47 kDa and a length of 498 amino acid residues. Computational analyses indicated that the designed construct was antigenic, non-toxic, non-allergenic, and possessed suitable physicochemical properties and predicted solubility, supporting its potential as a vaccine candidate for further investigation. Molecular docking analysis demonstrated favorable interactions between the MEV construct and selected Toll-like receptors (TLRs), while molecular dynamics (MD) simulations suggested the stability of the vaccine-receptor complexes throughout the simulation period. Furthermore, C-ImmSim-based immune simulation predicted the induction of both humoral and cellular immune responses following the proposed immunization schedule. Collectively, these findings highlight the potential of the designed MEV construct as a computationally optimized vaccine candidate and provide a framework for future experimental evaluation. Conclusion: This study presents a computationally designed MEV candidate against SARS-CoV-2 by integrating immunoinformatics approaches, structural modeling, molecular docking, molecular dynamics simulations, and immune response prediction. The findings suggest that the proposed MEV construct may possess favorable immunogenic and structural properties; however, experimental validation through

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19COVID-19 VaccinesEpitopes, T-LymphocytePhosphoproteinsSARS-CoV-2Spike Glycoprotein, CoronavirusEpitopes, B-LymphocyteHumansImmunoinformaticsMolecular Docking SimulationMolecular Dynamics SimulationProtein Subunit VaccinesT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerCoronavirus Nucleocapsid ProteinsCOVID-19 VaccinesEpitopes, B-LymphocyteEpitopes, T-Lymphocytenucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsProtein Subunit VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Gb-1immune simulationimmunoinformaticsmolecular dockingmolecular dynamics simulationmulti-epitope vaccineSARS-CoV-2

Identifiers

PMID42774152
PMCPMC13593759

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.